Therefore, N800 treatment may induce hepatic steatosis by impairing both Pparα-mediated mitochondrial β-oxidation and Foxa1/Srebp1c-mediated lipid metabolism gene expressions. The gene discussed is SREBF1; the disease is fatty liver disease.